Pancreatic Cancer Research

ResearcherDuke UniversityActive in the last 2 years

Rebekah Ruth White

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2185-8535; OpenAlex author ID A5045259580; NIH RePORTER profile ID 9771758. Sources: ClinicalTrials.gov.

Their work

Papers
33 (first author 6, last author 14)
Trials
1 (principal investigator on 1)
Grants
6
Labs led
2
Collaborators
62
Papers, trials and grants by year

2011: 1 paper · 2012: 6 papers · 2013: 3 papers · 2014: 1 paper, 1 grant · 2015: none · 2016: 1 paper, 1 grant · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 5 papers, 1 trial · 2025: 2 papers, 2 grants · 2026: 3 papers, 2 grants

Papers 33

  1. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. First author DOI 10.1093/oncolo/oyag416↗
  2. Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway. Last author DOI 10.1158/1535-7163.mct-25-0129↗
  3. Irreversible electroporation associated with improved overall survival vs standard of care for stage 3 pancreatic ductal adenocarcinoma First author DOI 10.64898/2026.05.19.26353144↗
  4. Local Ablation-Our next hope for pancreatic cancer immunotherapy? Co-author DOI 10.1016/j.canlet.2025.217445↗
  5. Irreversible electroporation with intratumoral plant virus immunotherapy induces systemic immunity in a metastatic model of pancreatic cancer. Last author DOI 10.1016/j.canlet.2025.218074↗
  6. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.27695↗
  7. Local ablative therapies and the effect on antitumor immune responses in pancreatic cancer - A review. Last author DOI 10.1016/j.heliyon.2023.e23551↗
  8. Local ablation in pancreatic cancer: some answers and more questions. First author DOI 10.1016/s2468-1253(24)00046-3↗
  9. Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment. Co-author DOI 10.1158/1535-7163.mct-23-0572↗
  10. Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Regis… First author DOI 10.3390/cancers16233894↗
  11. Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model. Last author DOI 10.1016/j.surg.2023.05.011↗
  12. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metasta… Last author DOI 10.1136/jitc-2022-006133↗
  13. Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model. Last author DOI 10.1007/s12672-022-00483-4↗
  14. The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. Co-author DOI 10.1245/s10434-021-09662-z↗
  15. Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival. Co-author DOI 10.3389/fonc.2021.817220↗
  16. Role of lymphadenectomy in resectable pancreatic cancer. Co-author DOI 10.1007/s00423-020-01980-2↗
  17. Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. Last author DOI 10.1016/j.surg.2020.04.059↗
  18. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from … Co-author DOI 10.1016/j.hpb.2018.12.004↗
  19. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Last author DOI 10.1158/2326-6066.cir-19-0101↗
  20. Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.ymthe.2018.02.018↗
  21. A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation. Last author DOI 10.3791/57265↗
  22. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 … Co-author DOI 10.1093/carcin/bgw093↗
  23. Neoadjuvant chemotherapy for localized pancreatic cancer: too little or too long? Co-author DOI 10.1245/s10434-014-3490-3↗
  24. Trends in racial disparities in pancreatic cancer surgery. Co-author DOI 10.1007/s11605-013-2304-4↗
  25. Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. Last author DOI 10.1089/nat.2013.0439↗
  26. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results r… Co-author DOI 10.1097/mpa.0b013e318291fbc5↗
  27. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? Last author DOI 10.1002/jso.23044↗
  28. A decision model of therapy for potentially resectable pancreatic cancer. First author DOI 10.1016/j.jss.2011.08.022↗
  29. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Last author DOI 10.1089/nat.2012.0353↗
  30. Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. Co-author DOI 10.1111/j.1532-5415.2011.03785.x↗
  31. Targeting eNOS in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-0057↗
  32. Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. Last author DOI 10.1172/jci62385↗
  33. Aptamers: potential applications to pancreatic cancer therapy. First author DOI 10.2174/187152011795677472↗

Trials 1

  1. Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer Principal investigator NCT06205849↗

Grants 6

  1. Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer R01CA282439↗
  2. Utilizing nucleic acid scavengers to elucidate how DNA/RNA-containing DAMPs promote pancreatic cancer metastasis and to mitigate such processes R01CA283740↗
  3. Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer R01CA254268↗
  4. 3D High Density Collagen I Improves Modeling of Metastatic Pancreatic Cancer R21CA306070↗
  5. Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification R21CA198287↗
  6. RNA Therapeutics for Pancreatic Cancer K08CA142903↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephen Philip Schoenberger · 2 shared papers, 1 shared grant, 2019–2026 · strength 1.52
  2. Bruce A. Sullenger · 4 shared papers, 1 shared grant, 2012–2026 · strength 1.47
  3. Jayanth S. Shankara Narayanan · 8 shared papers, 2018–2024 · strength 1.29
  4. Robert C.G. Martin · 6 shared papers, 2019–2026 · strength 1.21
  5. Stephanie Irene Fraley · 1 shared grant, 2025 · strength 1.07
  6. Suna Erdem · 6 shared papers, 2020–2024 · strength 1.03
  7. Partha Ray · 8 shared papers, 2012–2023 · strength 0.77
  8. Patricio Marcelo Polanco · 3 shared papers, 2024–2026 · strength 0.74
  9. Sean Patrick Cleary · 3 shared papers, 2024–2026 · strength 0.74
  10. Michael D. Kluger · 3 shared papers, 2024–2026 · strength 0.74
  11. Carlos H.F. Chan · 3 shared papers, 2024–2026 · strength 0.74
  12. Diego A. Vicente · 4 shared papers, 2019–2023 · strength 0.54
  13. Govindarajan Narayanan · 2 shared papers, 2026 · strength 0.54
  14. Chet W. Hammill · 2 shared papers, 2026 · strength 0.54
  15. Mathias Worni · 4 shared papers, 2013–2024 · strength 0.49
  16. David A. Iannitti · 2 shared papers, 2024–2026 · strength 0.47
  17. Yuan Chen · 2 shared papers, 2024–2026 · strength 0.46
  18. Jorge De la Torre · 2 shared papers, 2024–2026 · strength 0.46
  19. Zachary T. Berman · 1 shared paper, 2024 · strength 0.46
  20. Steven C. Katz · 3 shared papers, 2020–2023 · strength 0.45
  21. Benedict A. Capacio · 2 shared papers, 2020–2023 · strength 0.29
  22. Debbie K. Ledezma · 1 shared paper, 2025 · strength 0.27
  23. John D. Christein · 2 shared papers, 2019–2021 · strength 0.25
  24. Matthew John Weiss · 2 shared papers, 2019–2021 · strength 0.25
  25. James Don Murphy · 1 shared paper, 2021 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.